Table 4.
Number of patients and HC with abnormal deviation (as a percentage of the AIR) of the patient’s serum reactivity towards the studied antigens. FM—fibromyalgia, HC—heathy controls, ME/CFS—myalgic encephalomyelitis/chronic fatigue syndrome.
| Autoantibodies | ME/CFS(+)FM (n = 11) | ME/CFS(−)FM (n = 11) | HC (n = 11) | p-Values | ||||
|---|---|---|---|---|---|---|---|---|
| ME/CFS(+)FM vs. HC | ME/CFS(−) FM vs. HC | |||||||
| Anti-dsDNA AAb | 2 | (18.2%) | 3 | (27.3%) | 2 | (18.2%) | 1.00 | 0.66 |
| Anti-β2-GP AAb | 0 | (0.0%) | 3 | (27.3%) | 1 | (9.1%) | 1.00 | 0.57 |
| Anti-Fc-IgG AAb | 1 | (9.1%) | 1 | (9.1%) | 2 | (18.2%) | 0.61 | 0.61 |
| Anti-Collagen AAb | 4 | (36.4%) | 1 | (9.1%) | 3 | (27.3%) | 0.68 | 0.34 |
| Anti-CoM AAb | 1 | (9.1%) | 2 | (18.2%) | 2 | (18.2%) | 0.61 | 1.00 |
| Anti β1 Adr Re AAb | 2 | (18.2%) | 2 | (18.2%) | 3 | (27.3%) | 1.00 | 0.66 |
| Anti TrM-03 AAb | 1 | (9.1%) | 0 | (0.0%) | 3 | (27.3%) | 0.34 | 0.11 |
| Anti-ANCA AAb | 1 | (9.1%) | 2 | (18.2%) | 2 | (18.2%) | 0.61 | 1.00 |
| Anti-KiM-05 AAb | 1 | (9.1%) | 1 | (9.1%) | 1 | (9.1%) | 1.00 | 1.00 |
| Anti-LuM-02 AAb | 4 | (36.4%) | 5 | (45.5%) | 6 | (54.5%) | 0.43 | 0.70 |
| Anti-GaM-02 AAb | 1 | (9.1%) | 3 | (27.3%) | 2 | (18.2%) | 0.61 | 0.66 |
| Anti-ItM-07 AAb | 5 | (45.5%) | 3 | (27.3%) | 5 | (45.5%) | 1.00 | 0.42 |
| Anti-ScM AAb | 4 | (36.4%) | 3 | (27.3%) | 1 | (9.1%) | 0.17 | 0.34 |
| Anti-HeS-08 AAb | 0 | (0.0%) | 4 | (36.4% | 1 | (9.1%) | 1.00 | 0.53 |
| Anti-HMMP AAb | 1 | (9.1%) | 0 | (0.0%) | 2 | (18.2%) | 1.00 | 0.24 |
| Anti-Insulin AAb | 1 | (9.1%) | 2 | (18.2%) | 1 | (9.1%) | 1.00 | 0.61 |
| Anti-Ins-Re AAb | 1 | (9.1%) | 0 | (0.0%) | 1 | (9.1%) | 1.00 | 1.00 |
| Anti-TG AAb | 0 | (0.0%) | 3 | (27.3%) | 0 | (0.0%) | 1.00 | 0.11 |
| Anti-TSH-Re AAb | 1 | (9.1%) | 1 | (9.1%) | 1 | (9.1%) | 1.00 | 1.11 |
| Anti-Adr-D\C AAb | 1 | (9.1%) | 3 | (27.3%) | 2 | (18.2%) | 0.61 | 0.66 |
| Anti-SPr-06 AAb | 2 | (18.2%) | 4 | (36.4%) | 3 | (27.3%) | 0.66 | 0.68 |
| Anti-NF-200 AAb | 0 | (0.0%) | 1 | (9.1%) | 1 | (9.1%) | 1.00 | 1.00 |
| Anti-GFAP AAb | 1 | (9.1%) | 0 | (0.0%) | 0 | (0.0%) | 1.00 | 1.00 |
| Anti-S100 AAb | 1 | (9.1%) | 1 | (9.1%) | 1 | (9.1%) | 1.00 | 1.00 |
| Anti-MBP AAb | 0 | (0.0%) | 0 | (0.0%) | 2 | (18.2%) | 1.00 | 0.48 |
| Anti-V-Ca-Channel AAb | 0 | (0.0%) | 1 | (9.1%) | 1 | (9.1%) | 1.00 | 1.00 |
| Anti-Ach-Re AAb | 0 | (0.0%) | 1 | (9.1%) | 0 | (0.0%) | 1.00 | 1.00 |
| Anti-Glu-Re AAb | 1 | (9.1%) | 0 | (0.0%) | 2 | (18.2%) | 1.00 | 0.48 |
| Anti-GABA-Re AAb | 6 | (54.5%) | 5 | (45.5%) | 0 | (0.0%) | 0.0 | 0.06 |
| Anti-Dopa-Re AAb | 2 | (18.2%) | 2 | (18.2%) | 2 | (18.2%) | 1.00 | 1.00 |
| Anti-5HT-Re AAb | 1 | (9.1%) | 1 | (9.1%) | 1 | (9.1%) | 1.00 | 1.00 |
| Anti-μ-Opioid-Re AAb | 1 | (9.1%) | 2 | (18.2%) | 1 | (9.1%) | 1.00 | 0.61 |
| Anti-β-Endorphin AAb | 1 | (9.1%) | 3 | (27.3%) | 2 | (18.2%) | 0.61 | 0.66 |